NBD Nostrum Biodiscovery I Drug Discovery Company
- Established: 2016
- Employees: 7
- Crunchbase: Link to Crunchbase
Mission and Vision
NBD | Nostrum Biodiscovery is a biotechnological company, which creates drug discovery projects based on completely new mechanisms of action leading to the generation of first-in-class drug candidates.
NBD uses its own proprietary simulation technologies with structure-based simulations, artificial intelligence algorithms, and supercomputing capacity to speed up, increasing the success ratio, and profitability of the drug design process.If you are an Investor
NBD Key Metrics
NBD Business Model
The business model of the company will be based on two different branches that will alternate the high & moderate risk and that will also contain different ROI scenarios.
On one hand, NBD represents a stable platform that collaborates with pharmaceutical and biotech companies as well as CROs through the commercialization of CADD-based services.
On the other, a parallel activity has been developed focused on the generation of spinouts from NBD in association with client companies, public research institutions and/or VCs. NBD's spinout basis comes from the IP generated by a novel drug discovery built up from scratch based on a completely new mechanism of action.
This dual system aims to boost the business profitability of the core company, which generates stable revenues from CADD services and a high-risk & long-term expected income from the out-licensing of the projects or through the acquisition of the parent spinouts by third party companies.
The duality of this model will promote an increase in the success ratio of the spinouts, enabling them to find a specific and independent investor profile that matches with their activity and related therapeutic area, while creating a multiplier effect of the share valuation of NBD.
Some of NBD clients
- CROs: 20%
- Pharmaceutical companies: 40%
- Biotechs: 40%
Josep Oriol Nicolás
CEO I Chief Executive Officer
CSO I Chief Scientific Officer